CGTX
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Cognition Therapeutics, Inc. (CGTX) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C+ (2.5) | D+ (1.8) | D+ (1.5) | D+ (1.7) | C+ (2.6) | C- (2.0) |
| 2026-11-04 | C+ (2.5) | C (2.3) | D+ (1.6) | D+ (1.7) | C+ (2.7) | C (2.2) |
| 2026-10-28 | C+ (2.5) | C (2.2) | D+ (1.5) | C- (1.9) | C+ (2.7) | C (2.2) |
| 2026-10-21 | C+ (2.5) | C (2.2) | D+ (1.5) | C- (1.9) | C+ (2.6) | C (2.2) |
| 2026-10-14 | C+ (2.5) | C (2.2) | D+ (1.5) | C (2.4) | C+ (2.6) | C (2.3) |